Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

Psoriatic arthritis research

Psoriatic arthritis (PsA) is a type of arthritis that develops in some people with the skin condition psoriasis. It causes joints to become swollen and painful and is a long-term condition that can get progressively worse. It develops in 15% of people with psoriasis affecting around 150,000 people in the UK.

The study (OPTIMISE) is a collaboration with the University of Glasgow and King’s College London. It will test if it’s possible to predict whether people with PsA will respond to two different types of drug (two different types of biologics) leading to a reduction in inflamed joints and pain.

The team will first test if high levels of a type of blood cell, called Th17 cells, predicts a response to either or both of the two biologic drugs. They will then see if combining this blood result with other blood tests or an individual's pattern of arthritis improve the prediction. In this way they hope to develop a blood test that would predict the best biologic drug for each person, offering a more personalised approach and ensuring their disease is controlled quickly improving quality of life. 

Dr Coates said: “We have increasing numbers of drugs for psoriatic arthritis but very little evidence to tell us which drug we should pick for each individual patient. A recent small study in Japan suggested that choosing the biologic drug based on patients' blood Th17 cells could give better results than the doctors' choice. If our larger study supports this evidence, it will remove some of the guesswork for doctors who can’t know how to predict in advance which patient will respond best to each drug.  A simple blood test could predict which drug would be best for each patient before they start on treatment.” 

The OPTIMISE trial will be conducted in the department by the Experimental Medicine and Rheumatology group within the Oxford Clinical Trials Research Unit (OCTRU). If successful, this precision medicine approach could save money for the NHS and most importantly would improve patients' quality of life earlier. 

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.